The deal tape
A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.
What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.
186 deals in this cut, 102 of them safe to take a multiple from and 180 safe to take a premium from. Enterprise value is stated where a balance sheet and a share count could be read at the period end before announcement.
What this cut was bought at
Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.
| Measure | Deals | 25th | Median | 75th |
|---|---|---|---|---|
| EV / LTM EBITDA | 44 | 9.6x | 12.6x | 21.6x |
| EV / LTM revenue | 88 | 0.8x | 1.9x | 4.9x |
| Premium to unaffected price | 105 | 22% | 37% | 56% |
| Premium to 30-day VWAP | 21 | 22% | 31% | 42% |
Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.
| Target | Acquirer | Industry | EV | EV / EBITDA | EV / revenue | Premium | Filing |
|---|---|---|---|---|---|---|---|
Exact Sciences Corp 2025-11-19 · Public merger · $105.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Abbott Laboratories Strategic | Healthcare | $19bn | n.a. | 6.1x | 51% | DEFM14A Includes stock |
SEMrush Holdings, Inc. 2025-11-18 · Public merger · $12.00 a share | Adobe Inc. Strategic | Technology | $171m | 30.1x | 0.4x | 78% | DEFM14A All cash |
Sealed Air Corp/de 2025-11-16 · Public merger · $42.15 a share | Sword Purchaser, LLC Unclassified | Healthcare | $10bn | 10.5x | 1.9x | n.a. | DEFM14A All cash |
Merus N.V. 2025-11-12 (filed) · Public merger · $97.00 a share Held out of the multiples: EV / LTM revenue 186.2x above 60x | Not named in the filing Unclassified | Healthcare | $6.7bn | n.a. | 186.2x | n.a. | DEFM14A All cash |
TreeHouse Foods, Inc. 2025-11-10 · Public merger · $22.50 a share Held out of the multiples: EV / LTM EBITDA 237.7x outside 1x to 75x | Industrial F&B Investments III, Inc. Financial sponsor | Consumer & Retail | $2.6bn | 237.7x | 0.8x | 21% | DEFM14A All cash |
Gulf Island Fabrication Inc 2025-11-07 · Public merger · $12.00 a share | IES Holdings, Inc. Strategic | Industrials | $188m | 15.8x | 1.1x | n.a. | DEFM14A All cash |
Brighthouse Financial, Inc. 2025-11-06 · Public merger · $70.00 a share | Aquarian Holdings VI L.P. Strategic | Financials | $551m | n.a. | 0.1x | 37% | DEFM14A All cash |
Forge Global Holdings, Inc. 2025-11-05 · Public merger · $45.00 a share Held out of the premiums: premium of 170%: distressed or misread | The Charles Schwab Corporation Strategic | Financials | $551m | n.a. | 5.9x | 170% | DEFM14A All cash |
LakeShore Biopharma Co., Ltd. 2025-11-04 · Take-private · $0.90 a share Board book on file → | Crystal Peak Holdings Inc. Financial sponsor | Healthcare | $61m | n.a. | 0.7x | 15% | SC 13E3 All cash |
CNL Healthcare Properties, Inc. 2025-11-04 · Public merger · $2.32 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | SSL Sparti LLC Strategic | Real Estate | $914m | 10.7x | 2.6x | n.a. | DEFM14A Includes stock |
DENNY'S Corp 2025-11-03 · Public merger · $6.25 a share | Sparkle Topco Corp. Unclassified | Consumer & Retail | $579m | 10.4x | 1.3x | 52% | DEFM14A All cash |
Kenvue Inc. 2025-11-02 · Public merger · $3.50 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Vesta Sub I, Inc. Strategic | Materials | $6.3bn | 2.1x | 0.4x | 8% | DEFM14A Includes stock |
Civitas Resources, Inc. 2025-11-02 · Public merger · $3.77 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | SM Energy Strategic | Energy | $5.4bn | n.a. | 1.1x | n.a. | DEFM14A Includes stock |
IF Bancorp, Inc. 2025-10-29 · Public merger · $27.20 a share | ServBanc Holdco, Inc. Unclassified | Financials | $68m | n.a. | n.a. | n.a. | DEFM14A All cash |
REV Group, Inc. 2025-10-29 · Public merger · $8.71 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Terex Corporation Strategic | Industrials | $479m | 2.5x | 0.2x | n.a. | DEFM14A Includes stock |
Csg Systems International Inc 2025-10-29 · Public merger · $80.70 a share | Inc. 169 Invern Strategic | Technology | $2.7bn | 17.8x | 2.2x | 17% | DEFM14A All cash |
Olympic Steel Inc 2025-10-28 · Public merger · $39.26 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Crimson MS Corp. Strategic | Industrials | $673m | 9.7x | 0.3x | 32% | DEFM14A Includes stock |
Jamf Holding Corp. 2025-10-28 · Public merger · $13.05 a share | Jawbreaker Parent, Inc. Unclassified | Technology | $1.2bn | n.a. | 1.7x | 36% | DEFM14A All cash |
First Foundation Inc. 2025-10-27 · Public merger · $5.37 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Not named in the filing Unclassified | Financials | -$1.3bn | n.a. | -36.3x | n.a. | DEFM14A Includes stock |
Sonnet BioTherapeutics Holdings, Inc. 2025-10-27 (filed) · Public merger · $1.25 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Biosub Inc. Strategic | Healthcare | $25m | n.a. | 0.6x | n.a. | DEFM14A Includes stock |
Avidity Biosciences, Inc. 2025-10-25 · Public merger · $72.00 a share Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 426.4x above 60x | Distribution Agreement Strategic | Healthcare | $8.9bn | n.a. | 426.4x | 46% | DEFM14A Includes stock |
Plymouth Industrial REIT, Inc. 2025-10-24 · Public merger · $22.00 a share | Plymouth Industrial OP, LP Strategic | Real Estate | $938m | n.a. | 4.9x | n.a. | DEFM14A All cash |
Sotherly Hotels Inc. 2025-10-24 · Public merger · $2.25 a share Held out of the premiums: premium of 153%: distressed or misread | KW Kingfisher LLC Strategic | Real Estate | $357m | 9.7x | 2.0x | 153% | DEFM14A All cash |
MidWestOne Financial Group, Inc. 2025-10-23 · Public merger · $37.65 a share Held out of the multiples: consideration includes stock: the cash figure is not the price | Not named in the filing Unclassified | Financials | $605m | n.a. | n.a. | n.a. | DEFM14A Includes stock |
Hologic Inc 2025-10-21 · Public merger · $76.00 a share | Hopper Parent Inc. Unclassified | Healthcare | $17bn | 17.0x | 4.2x | 27% | DEFM14A All cash |
How to use a set like this
Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.
Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.
What each column means
- Enterprise value.
- Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
- Premium.
- The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
- Deal type.
- A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
- In doubt.
- A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.
Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More